By analyzing the prognostic value of IKZF1 status in our patient cohort, a decreasing rate of EFS was observed in patents with normal vs IKZF1 del vs IKZF1 plus genotype; however, the difference between the latter two categories did not reach statistical significance (Fig.
← all excerpts
PersonALL: a genetic scoring guide for personalized risk assessment in pediatric B-cell precursor acute lymphoblastic leukemia.
1
—
—